Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 301-217 Queen St West TORONTO ON M5V 0R2 |
Tel: | N/A |
Website: | https://awaknlifesciences.com |
IR: | See website |
Key People | ||
George Scorsis Independent Chairman of the Board | Anthony Tennyson President, Chief Executive Officer, Director | Katherine Butler Chief Financial Officer |
James Collins Chief Operating Officer | Shaun Mcnulty Chief Scientific Officer | David Nutt Chief Research Officer |
Benjamin Sessa Chief Medical Officer | Jonathan Held Chief Business Officer, Secretary |
Business Overview |
Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and commercializing of therapeutics to treat addiction with a focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe. The Company operates in the United Kingdom (UK), Ireland and Canada. |
Financial Overview |
For the nine months ended 31 October 2023, Awakn Life Sciences Corp revenues increased from C$0K to C$66K. Net loss before extraordinary items decreased 44% to C$2.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Foreign exchange loss (gain) increase from C$423K (expense) to C$371K (income), Sales and marketing decrease of 64% to C$310K (expense). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $6.26M as of Oct 31, 2023 |
Annual revenue (TTM): | $0.54M as of Oct 31, 2023 |
EBITDA (TTM): | -$5.10M as of Oct 31, 2023 |
Net annual income (TTM): | -$5.01M as of Oct 31, 2023 |
Free cash flow (TTM): | -$4.20M as of Oct 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 38,591,197 as of Oct 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |